ATE475675T1 - Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen - Google Patents

Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen

Info

Publication number
ATE475675T1
ATE475675T1 AT01928324T AT01928324T ATE475675T1 AT E475675 T1 ATE475675 T1 AT E475675T1 AT 01928324 T AT01928324 T AT 01928324T AT 01928324 T AT01928324 T AT 01928324T AT E475675 T1 ATE475675 T1 AT E475675T1
Authority
AT
Austria
Prior art keywords
immunogenicity
procariotic
plague
antigens
peptides
Prior art date
Application number
AT01928324T
Other languages
English (en)
Inventor
Yvonne Paterson
George Raymond Gunn Iii
Christian Peters
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Priority claimed from PCT/US2001/009736 external-priority patent/WO2001072329A1/en
Application granted granted Critical
Publication of ATE475675T1 publication Critical patent/ATE475675T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT01928324T 2000-03-29 2001-03-26 Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen ATE475675T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/537,642 US6855320B2 (en) 2000-03-29 2000-03-29 Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US09/735,450 US6767542B2 (en) 2000-03-29 2000-12-13 Compositions and methods for enhancing immunogenicity of antigens
PCT/US2001/009736 WO2001072329A1 (en) 2000-03-29 2001-03-26 Compositions and methods for enhancing immunogenicity of antigens

Publications (1)

Publication Number Publication Date
ATE475675T1 true ATE475675T1 (de) 2010-08-15

Family

ID=24143505

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01928324T ATE475675T1 (de) 2000-03-29 2001-03-26 Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen

Country Status (4)

Country Link
US (2) US6855320B2 (de)
AT (1) ATE475675T1 (de)
DE (1) DE60142689D1 (de)
IL (1) IL151942A (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8791237B2 (en) * 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US7662396B2 (en) * 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8114414B2 (en) * 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US6051237A (en) * 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US20070264279A1 (en) * 1994-11-08 2007-11-15 Claudia Gravekamp Compositions and methods comprising a MAGE-b antigen
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
EP1303299B1 (de) * 2000-03-29 2010-07-28 The Trustees of The University of Pennsylvania Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7700344B2 (en) * 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
WO2003102168A1 (en) * 2002-05-29 2003-12-11 The Regents Of The University Of California Attenuated listeria spp. and methods for using the same
US8337861B2 (en) * 2003-01-09 2012-12-25 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
DK1592441T3 (da) * 2003-02-06 2012-05-14 Aduro Biotech Listeria, hvis indtrængen i ikke-phagocytiske celler er svækket, vacciner omfattende listeria og fremgangsmåder til anvendelse deraf
WO2004084936A2 (en) * 2003-02-06 2004-10-07 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
CA2577306A1 (en) 2004-08-13 2006-02-16 The Trustees Of The University Of Pennsylvania Methods for constructing antibiotic resistance free vaccines
US7858097B2 (en) * 2004-08-13 2010-12-28 The Trustees Of The University Of Pennsylvania Antibiotic resistance free Listeria strains and methods for constructing and using same
AU2005271247A1 (en) * 2004-08-13 2006-02-16 The Trustees Of The University Of Pennsylvania Antibiotic resistance free DNA vaccines
US7855064B2 (en) * 2004-08-13 2010-12-21 The Trustees Of The University Of Pennsylvania Antibiotic resistance free vaccines and methods for constructing and using same
EP2860253B1 (de) * 2006-03-01 2018-08-01 Aduro Biotech, Inc. Manipulierte Listerien und Anwendungsverfahren dafür
US20070207171A1 (en) * 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US9370557B2 (en) * 2006-06-15 2016-06-21 The University Court Of The University Of Glasgow Adjuvant compounds
EP2056849A4 (de) * 2006-08-04 2010-09-08 Univ Pennsylvania Verfahren und zusammensetzungen zur behandlung von ige-vermittelten erkrankungen
EP2061800B1 (de) * 2006-08-15 2015-07-29 The Trustees of the University of Pennsylvania Zusammensetzungen mit hmw-maa und fragmenten davon sowie verfahren zu ihrer verwendung
US8268326B2 (en) * 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
US8277797B2 (en) 2006-11-22 2012-10-02 The Regents Of The University Of California Interferon-β production modulating Listeria strains and methods for using same
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
EP2853269B1 (de) 2008-05-19 2019-05-01 Advaxis, Inc. Doppeltes Freisetzungssystem für heterologe Antigene umfassend einen rekombinanten Listeria - Stamm, attenuiert durch Mutation von dal / dat und Deletion von ActA, umfassend ein Nukleinsäuremolekül, das ein Listeriolysin O - Prostata - spezifisches Antigen - Fusionsprotein codiert
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
WO2010102140A1 (en) 2009-03-04 2010-09-10 The Trustees Of The University Of Pennsylvania Compositions comprising angiogenic factors and methods of use thereof
EP2498808A4 (de) * 2009-11-11 2014-01-08 Advaxis Zusammensetzungen und verfahren zur verhinderung von fluchtmutationen bei der behandlung von tumoren mit her2/neu-überexpression
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US20110223187A1 (en) * 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
US20110305724A1 (en) * 2010-04-19 2011-12-15 Yvonne Paterson Immunotherapeutic, anti-tumorigenic compositions and methods of use thereof
CN103282048B (zh) 2010-10-01 2017-05-17 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
WO2012112317A1 (en) 2011-02-15 2012-08-23 Albert Einstein College Of Medicine Of Yeshiva University Radiobacteria for therapy of cancer
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
KR20140134695A (ko) 2012-03-12 2014-11-24 어드박시스, 인크. 리스테리아 백신 치료 후 억제 세포 기능 저해
MX2015008329A (es) 2012-12-27 2016-03-01 Aduro Biotech Inc Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos.
SG11201606677XA (en) 2014-02-18 2016-09-29 Advaxis Inc Biomarker directed multi-target immunotherapy
MX2016011114A (es) * 2014-02-25 2017-02-20 Advaxis Inc Composiciones y metodos para el tratamiento de tumores que sobreexpresan her2/neu.
AU2015250111A1 (en) 2014-04-24 2016-12-08 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
MX2016014367A (es) 2014-05-02 2017-06-30 Univ Pennsylvania Combinación de inmunoterapia y radioterapia para el tratamiento de canceres positivos a her-2.
MA40344A (fr) 2014-07-18 2016-01-21 Advaxis Inc Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer
US20160228530A1 (en) 2014-10-14 2016-08-11 The Trustees Of The University Of Pennsylvania Combination therapy for use in cancer therapy
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
CA3035591A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
CN111356760A (zh) 2017-09-19 2020-06-30 阿德瓦希斯公司 细菌或李斯特菌菌株的冻干组合物和方法
EP3762719A1 (de) 2018-03-09 2021-01-13 Advaxis, Inc. Zusammensetzungen und verfahren zur beurteilung der attenuierung und infektiosität von listeria-stämmen
US20210239681A1 (en) 2018-04-27 2021-08-05 Advaxis, Inc. Compositions and methods for evaluating potency of listeria-based immunotherapeutics
CA3184128A1 (en) 2020-06-23 2021-12-30 Kathleen Barnes Methods for diagnosing respiratory pathogens and predicting covid-19 related outcomes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262177A (en) * 1986-02-07 1993-11-16 Oncogen Recombinant viruses encoding the human melanoma-associated antigen
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US6051237A (en) * 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
EP0902086A1 (de) 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberkolose Impfstoff

Also Published As

Publication number Publication date
DE60142689D1 (de) 2010-09-09
US6767542B2 (en) 2004-07-27
US20020025323A1 (en) 2002-02-28
IL151942A (en) 2009-07-20
US20020028206A1 (en) 2002-03-07
US6855320B2 (en) 2005-02-15

Similar Documents

Publication Publication Date Title
DE60142689D1 (de) Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
DE60232577D1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
ATE374042T1 (de) Fc-fusionsproteine zur erhöhung der immunogenität von protein- und peptid-antigenen
DE60325892D1 (de) Stellungs- und verwendungsverfahren
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
WO2003102157A3 (en) Synthetic antibody phage libraries
DE69942274D1 (de) Methoden zur amyloidentfernung mit anti-amyloid-antikörper
WO2004065416A3 (en) Synthetic antibody phage libraries
ATE524194T1 (de) Antigene polypeptide
NO20000850L (no) Vaksine
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
ATE387629T1 (de) Gemeinsame epitope von antigenen aus einer multigen-familie
ATE389668T1 (de) Tumorantigen
MY148646A (en) Anti-psgl-1 antibodies
WO2006036550A3 (en) Listeria-based and llo-based vaccines
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
DK1370284T3 (da) Bakteriofag-medieret immunisering
ES2143996T3 (es) Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv.
ATE397081T1 (de) Erhöhte expression von proteinen mittels gfp
DE69840326D1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
DK218886A (da) Tvaerreaktive og beskyttende epitoper af circumsporozoit-proteiner
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
MY144766A (en) Plant virus coat fusion proteins with gdf8 epitopes and vaccines thereof
BR0311720A (pt) Método para mapear e eliminar epitopos de células t
DK1545594T3 (da) Bakteriofag-medieret immunisering mod Hepatitis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties